


First Clinical Research Stock Index (FCRI)

Market Activity

FCRI declined 6% in February. Pharmas and biotechs declined 4% and the general market declined 2%. Six FCRI stocks rose and 12 declined.

Significant gainers include Bio-Imaging Technologies (+13%) and eTrials Worldwide (+10%). Significant decliners include Encorium Group (-25%), PRA International (-18%), Datatrak International (-17%), Kendle International (-11%) and PPD (-10%).



Notes on Indices

- **First Clinical Research Index (FCRI)**. Calculated as the mean average percentage change from baseline, dividends excluded, adjusted for stock splits. In other words, the indices are not weighted for stock price or market capitalization. Index components may change from time to time based on new listings, mergers and other factors. Components include all 18 publicly-traded clinical research stocks: Bio-Imaging Technologies (BITI), Clinphone Group Ltd (CNP), Encorium Group (ENCO), Covance (CVD), Datatrak International (DATA), eResearchTechnology (ERES), eTrials Worldwide (ETWC), ICON (ICLR), Averion International (AVRO), Kendle International (KNDL), MDS Pharma Services (MDZ), PAREXEL International (PRXL), PharmaNet Development Group (PDGI), Pharsight (PHST), Phase Forward (PFWF), PPD (PPDI), PRA International (PRAI), and Premier Research Group (PRG).
- **S&P 500 Index (SPX)**. Capitalization-weighted representative sample of 500 mostly large-capitalization companies in leading industries of the U.S. economy.
- **S&P 500 Pharmaceutical Index (S5PHARX)**. Capitalization-weighted S&P 500 companies engaged in research, development or production of pharmaceuticals.
- **S&P 500 Biotechnology Index (S5BIOTX)**. Capitalization-weighted S&P 500 companies primarily involved in development, manufacturing or marketing of products based on advanced biotechnology research.

Stock and index prices are available at <http://www.bloomberg.com/> and <http://finance.yahoo.com/>.